Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 12, 2024
Product Development

Cambrian explosion of ADCs at AACR24

Conference showcases six emerging ADC payload types, and trends in antigen pairs for bispecific ADCs
BioCentury | Apr 21, 2023
Product Development

ADC advances at AACR: target diversity, optimizing internalization

BioCentury’s analysis of the AACR 2023 abstracts highlights innovation in antibody-drug conjugate design
BioCentury | Sep 13, 2019
Distillery Therapeutics

Peptide-macrocycle conjugates for breast cancer

BioCentury | Nov 26, 2018
Distillery Techniques

Drug delivery

BioCentury | Mar 13, 2018
Distillery Techniques

Drug delivery

BioCentury | Sep 11, 2017
Distillery Techniques

Drug delivery

BioCentury | Jun 15, 2017
Tools & Techniques

Breaking the barrier

Companies are finally finding ways to develop cell-penetrating biologics
BioCentury | Jan 31, 2017
Distillery Therapeutics

Ophthalmic disease

BioCentury | Oct 24, 2016
Clinical News

Luminate: Phase IIb data

BioCentury | Oct 10, 2016
Clinical News

Luminate: Completed Phase IIb enrollment

Items per page:
1 - 10 of 37